{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:24:10Z","timestamp":1789759450067,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contactlensjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contact Lens and Anterior Eye"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clae.2023.102091","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T07:41:20Z","timestamp":1699602080000},"page":"102091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Platelet-rich plasma for treating dry eye disease \u2013 A systematic review and meta-analysis"],"prefix":"10.1016","volume":"47","author":[{"given":"Prince","family":"Kwaku Akowuah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuemeka","family":"Junior Obinwanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1612-4350","authenticated-orcid":false,"given":"Ebenezer","family":"Owusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvester","family":"Kyeremeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwaku","family":"Bonsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy Akua Afriyie","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Akyaa Akomeah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Kyei Nkansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Kobia-Acquah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clae.2023.102091_b0005","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102091_b0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jtos.2015.11.002","article-title":"Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review","volume":"14","author":"McDonald","year":"2016","journal-title":"Ocular Surface"},{"key":"10.1016\/j.clae.2023.102091_b0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2147\/CEOR.S36352","article-title":"Impact of dry eye on work productivity","volume":"4","author":"Yamada","year":"2012","journal-title":"ClinicoEconomics and Outcomes Research"},{"key":"10.1016\/j.clae.2023.102091_b0020","first-page":"71","article-title":"Pathophysiology, diagnosis and treatment of dry eye","volume":"112","author":"Messmer","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.clae.2023.102091_b0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1542-0124(12)70040-X","article-title":"Patient-reported symptoms in dry eye disease","volume":"4","author":"Nichols","year":"2006","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102091_b0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jtos.2016.04.005","article-title":"Understanding symptoms and quality of life in patients with dry eye syndrome","volume":"14","author":"Barabino","year":"2016","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102091_b0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jtos.2018.11.003","article-title":"The impact of dry eye disease treatment on patient satisfaction and quality of life: a review","volume":"17","author":"Gomes","year":"2019","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102091_b0040","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","article-title":"Impact of dry eye syndrome on vision-related quality of life","volume":"143","author":"Miljanovi\u0107","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clae.2023.102091_b0045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/eye.2017.289","article-title":"Assessment and management of dry eye disease","volume":"32","author":"Buckley","year":"2018","journal-title":"Eye"},{"key":"10.1016\/j.clae.2023.102091_b0050","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/NHH.0000000000000652","article-title":"Dry eye disease: prevalence, assessment, and management","volume":"36","author":"Rouen","year":"2018","journal-title":"Home Healthc Now"},{"key":"10.1016\/j.clae.2023.102091_b0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","article-title":"Locally administered ocular corticosteroids: benefits and risks","volume":"25","author":"McGhee","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.clae.2023.102091_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2006.10.044","article-title":"Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers","volume":"114","author":"Alio","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clae.2023.102091_b0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14712598.2021.1945030","article-title":"Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus","volume":"22","author":"Anitua","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clae.2023.102091_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.aanat.2020.151528","article-title":"The use of plasma rich in growth factors (PRGF) in guided tissue regeneration and guided bone regeneration. a review of histological, immunohistochemical, histomorphometrical, radiological and clinical results in humans","volume":"231","author":"Solakoglu","year":"2020","journal-title":"Ann Anat"},{"key":"10.1016\/j.clae.2023.102091_b0075","doi-asserted-by":"crossref","first-page":"2457620","DOI":"10.1155\/2017\/2457620","article-title":"Autologous platelet-rich plasma eye drops for the treatment of post-LASIK chronic ocular surface syndrome","volume":"2017","author":"Alio","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.clae.2023.102091_b0080","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000100933","article-title":"Symptomatic dry eye treatment with autologous platelet-rich plasma","volume":"39","author":"Alio","year":"2007","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.clae.2023.102091_b0085","doi-asserted-by":"crossref","first-page":"308","DOI":"10.5935\/0034-7280.20160061","article-title":"Platelet-rich plasma in diabetic dry eye disease","volume":"75","author":"Ribeiro","year":"2016","journal-title":"Rev Bras Oftalmol"},{"key":"10.1016\/j.clae.2023.102091_b0090","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bbmt.2016.05.023","article-title":"A single-center pilot prospective study of topical application of platelet-derived eye drops for patients with ocular chronic graft-versus-host disease","volume":"22","author":"Zallio","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clae.2023.102091_b0095","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8406832","article-title":"The effect of autologous platelet lysate eye drops: an in vivo confocal microscopy study","volume":"2016","author":"Fea","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clae.2023.102091_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8091478","article-title":"Blood-based treatments for severe dry eye disease: the need of a consensus","volume":"8","author":"Bernabei","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.clae.2023.102091_b0105","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.2147\/OPTH.S265701","article-title":"Human platelets and derived products in treating ocular surface diseases \u2013 a systematic review","volume":"14","author":"You","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clae.2023.102091_b0110","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"7","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.clae.2023.102091_b0115","first-page":"14","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clae.2023.102091_b0120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"10.1016\/j.clae.2023.102091_b0125","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1111\/aos.13907","article-title":"Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma","volume":"97","author":"Garc\u00eda-Conca","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.clae.2023.102091_b0130","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4103\/djo.djo_16_21","article-title":"Autologous serum eye drops versus lacrimal gland injection of platelet-rich plasma for severe dry eye","volume":"22","author":"Allam","year":"2021","journal-title":"Delta Journal of Ophthalmology"},{"key":"10.1016\/j.clae.2023.102091_b0135","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.21608\/ejhm.2021.180354","article-title":"Evaluating the role of autologous platelet-rich-plasma in the treatment of dry eye disease","volume":"84","author":"Emam","year":"2021","journal-title":"Egypt J Hosp Med"},{"key":"10.1016\/j.clae.2023.102091_b0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/ejos.ejos_26_21","article-title":"Assessment of the efficacy of platelet-rich plasma injections in the management of severe dry eye","volume":"114","author":"Elessawy","year":"2021","journal-title":"Journal of the Egyptian Ophthalmological Society"},{"key":"10.1016\/j.clae.2023.102091_b0145","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/bjophthalmol-2018-312072","article-title":"Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye","volume":"103","author":"Avila","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clae.2023.102091_b0150","first-page":"2542","article-title":"Autologous Platelet Rich Plasma versus Autologous Serum Eye Drops in Treatment of Severe Dry Eye Disease","volume":"4","author":"Mohammad","year":"2022","journal-title":"International Journal of Medical Arts"},{"key":"10.1016\/j.clae.2023.102091_b0155","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4103\/ijo.IJO_2595_21","article-title":"Autologous platelet-rich plasma eye drop versus artificial tear eye drop for symptomatic dry eye disease: a prospective comparative interventional study","volume":"70","author":"Rawat","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.clae.2023.102091_b0160","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.21608\/ejhm.2019.42651","article-title":"Assessment of autologous (platelet-rich-plasma) as a monotherapy for treatment of dry eye disease","volume":"76","author":"Wahdan","year":"2019","journal-title":"Egypt J Hosp Med"},{"key":"10.1016\/j.clae.2023.102091_b0165","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.3390\/jcm12093126","article-title":"The comparison between the composition of 100% autologous serum and 100% platelet-rich plasma eye drops and their impact on the treatment effectiveness of dry eye disease in primary sjogren syndrome","volume":"12","author":"Wr\u00f3bel-Dudzi\u0144ska","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.clae.2023.102091_b0170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40123-017-0100-z","article-title":"Treatment of dry eye disease with autologous platelet-rich plasma: a prospective, interventional","volume":"6","author":"Alio","year":"2017","journal-title":"Non-Randomized Study Ophthalmol Ther"},{"key":"10.1016\/j.clae.2023.102091_b0175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bmt.2016.221","article-title":"Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD","volume":"52","author":"Pezzotta","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clae.2023.102091_b0180","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/ICO.0000000000000016","article-title":"Restoration of human lacrimal function following platelet-rich plasma injection","volume":"33","author":"Avila","year":"2014","journal-title":"Cornea"},{"key":"10.1016\/j.clae.2023.102091_b0185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000444496","article-title":"Safety and efficacy of autologous plasma rich in growth factors eye drops for the treatment of evaporative dry eye","volume":"56","author":"Merayo-Lloves","year":"2016","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.clae.2023.102091_b0190","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jop.2016.0166","article-title":"The effect of immunologically safe plasma rich in growth factor eye drops in patients with sj\u00f6gren syndrome","volume":"33","author":"Sanchez-Avila","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.clae.2023.102091_b0195","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1120672118818943","article-title":"Plasma rich in growth factors for the treatment of dry eye from patients with graft versus host diseases","volume":"30","author":"Sanchez-Avila","year":"2020","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clae.2023.102091_b0200","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000487951","article-title":"plasma rich in growth factors for the treatment of dry eye after LASIK surgery","volume":"60","author":"Sanchez-Avila","year":"2018","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.clae.2023.102091_b0205","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2147\/OPTH.S367807","article-title":"Autologous platelet-rich plasma drops for evaporative dry eye disease from meibomian gland dysfunction: a pilot study","volume":"16","author":"Murtaza","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clae.2023.102091_b0210","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10792-017-0582-7","article-title":"Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops","volume":"38","author":"Sanchez-Avila","year":"2018","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.clae.2023.102091_b0215","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102091_b0220","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2174\/138920112800624355","article-title":"The role of \u201ceye platelet rich plasma\u201d (E-PRP) for wound healing in ophthalmology","volume":"13","author":"Alio","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.clae.2023.102091_b0225","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/bjo.2004.044347","article-title":"Autologous serum eye drops for ocular surface disorders","volume":"88","author":"Geerling","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clae.2023.102091_b0230","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/ICO.0000000000000271","article-title":"Long-term use of autologous serum 50% eye drops for the treatment of dry eye disease","volume":"33","author":"Hussain","year":"2014","journal-title":"Cornea"},{"key":"10.1016\/j.clae.2023.102091_b0235","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.tjo.2014.09.001","article-title":"Easy-to-prepare autologous platelet-rich plasma in the treatment of refractory corneal ulcers","volume":"5","author":"Wu","year":"2015","journal-title":"Taiwan J Ophthalmol"},{"key":"10.1016\/j.clae.2023.102091_b0240","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.preteyeres.2014.10.001","article-title":"Clinical staining of the ocular surface: mechanisms and interpretations","volume":"44","author":"Bron","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.clae.2023.102091_b0245","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II diagnostic methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clae.2023.102091_b0250","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/09537104.2012.684730","article-title":"The role of platelet-rich plasma in tissue regeneration","volume":"24","author":"Alsousou","year":"2013","journal-title":"Platelets"},{"key":"10.1016\/j.clae.2023.102091_b0255","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1097\/ICO.0b013e31820d86d6","article-title":"Efficacy of plasma rich in growth factors for the treatment of dry eye","volume":"30","author":"L\u00f3pez-Plandolit","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.clae.2023.102091_b0260","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.exer.2019.01.003","article-title":"Enhancement of corneal epithelium cell survival, proliferation and migration by red light: relevance to corneal wound healing","volume":"180","author":"N\u00fa\u00f1ez-\u00c1lvarez","year":"2019","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.clae.2023.102091_b0265","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.brainresbull.2009.08.024","article-title":"Growth factors and corneal epithelial wound healing","volume":"81","author":"Yu","year":"2010","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.clae.2023.102091_b0270","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40123-016-0051-9","article-title":"Solid platelet rich plasma in corneal surgery","volume":"5","author":"Arnalich","year":"2016","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.clae.2023.102091_b0275","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s10384-012-0175-y","article-title":"Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis","volume":"56","author":"Kim","year":"2012","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.clae.2023.102091_b0280","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/ICO.0b013e3182114661","article-title":"Topical autologous platelet-rich plasma eyedrops for acute corneal chemical injury","volume":"31","author":"Panda","year":"2012","journal-title":"Cornea"}],"container-title":["Contact Lens and Anterior Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367048423003302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367048423003302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T01:22:20Z","timestamp":1761268940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367048423003302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1367048423003302"],"URL":"https:\/\/doi.org\/10.1016\/j.clae.2023.102091","relation":{},"ISSN":["1367-0484"],"issn-type":[{"value":"1367-0484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet-rich plasma for treating dry eye disease \u2013 A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Contact Lens and Anterior Eye","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clae.2023.102091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102091"}}